首页 > 最新文献

Medicinal Chemistry最新文献

英文 中文
Unlocking the Multifunctional Therapeutic Potential of Herbacetin: A Flavone derived Scaffold. 解锁herbacettin的多功能治疗潜力:一种黄酮衍生支架。
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-24 DOI: 10.2174/0115734064389091250719051643
Navin Kumar Tailor

Herbacetin (HBT), a naturally occurring flavone, exhibits broad therapeutic -- potential, including anti-cancer, anti-inflammatory, antioxidant, antimicrobial, neuroprotective, and anti-diabetic effects, by modulating key signaling pathways such as NF-κB, PI3K/AKT, AP-1, SGK1/FoxO1, AMPK, SIRT1, MMP9, and NLRP3. It also inhibits several critical enzymes, including ornithine decarboxylase, ATP-citrate lyase, SGK1, AChE, α-glucosidase, and CYP3A4. In the context of cancer, HBT has shown particularly promising activity against breast cancer, liver carcinoma, human colon cancer, and epidermal carcinoma. Structurally, HBT shares significant similarity with well-known flavonoids such as quercetin and kaempferol, and the availability of established total synthetic methodologies makes it an attractive candidate for synthetic chemists. However, the structural modification and comprehensive evaluation of ' 'HBT's biological activity remain underexplored. This review highlights its isolation, total synthesis, pharmacological properties, molecular targets, and future directions, emphasizing the versatility of the HBT scaffold as a promising foundation for the development of novel therapeutic agents.

Herbacetin (HBT)是一种天然存在的黄酮,通过调节NF-κB、PI3K/AKT、AP-1、SGK1/FoxO1、AMPK、SIRT1、MMP9和NLRP3等关键信号通路,具有广泛的治疗潜力,包括抗癌、抗炎、抗氧化、抗菌、神经保护和抗糖尿病作用。它还抑制几种关键酶,包括鸟氨酸脱羧酶、atp -柠檬酸水解酶、SGK1、AChE、α-葡萄糖苷酶和CYP3A4。在癌症方面,HBT已显示出对乳腺癌、肝癌、人类结肠癌和表皮癌特别有希望的活性。在结构上,HBT与众所周知的类黄酮(如槲皮素和山奈酚)具有显著的相似性,并且已建立的全合成方法的可用性使其成为合成化学家的一个有吸引力的候选者。然而,HBT的结构修饰和生物活性的综合评价还有待进一步研究。本文综述了HBT支架的分离、全合成、药理性质、分子靶点和未来发展方向,强调了HBT支架的多功能性,为开发新型治疗药物奠定了良好的基础。
{"title":"Unlocking the Multifunctional Therapeutic Potential of Herbacetin: A Flavone derived Scaffold.","authors":"Navin Kumar Tailor","doi":"10.2174/0115734064389091250719051643","DOIUrl":"https://doi.org/10.2174/0115734064389091250719051643","url":null,"abstract":"<p><p>Herbacetin (HBT), a naturally occurring flavone, exhibits broad therapeutic -- potential, including anti-cancer, anti-inflammatory, antioxidant, antimicrobial, neuroprotective, and anti-diabetic effects, by modulating key signaling pathways such as NF-κB, PI3K/AKT, AP-1, SGK1/FoxO1, AMPK, SIRT1, MMP9, and NLRP3. It also inhibits several critical enzymes, including ornithine decarboxylase, ATP-citrate lyase, SGK1, AChE, α-glucosidase, and CYP3A4. In the context of cancer, HBT has shown particularly promising activity against breast cancer, liver carcinoma, human colon cancer, and epidermal carcinoma. Structurally, HBT shares significant similarity with well-known flavonoids such as quercetin and kaempferol, and the availability of established total synthetic methodologies makes it an attractive candidate for synthetic chemists. However, the structural modification and comprehensive evaluation of ' 'HBT's biological activity remain underexplored. This review highlights its isolation, total synthesis, pharmacological properties, molecular targets, and future directions, emphasizing the versatility of the HBT scaffold as a promising foundation for the development of novel therapeutic agents.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitosan-Based Materials: A Comprehensive Review on Anticancer Drug Development. 壳聚糖基材料:抗癌药物研究综述
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-22 DOI: 10.2174/0115734064388263250710083810
Faris J Tayeb, Mohammed Fareed Felemban, Amal Adnan Ashour, Alaa Shafie

Cancer remains one of the most formidable global health threats, responsible for millions of deaths annually due to the uncontrolled proliferation and spread of abnormal cells. The development of effective anticancer therapies is crucial, as anticancer drugs target key cellular mechanisms, including DNA replication, apoptosis, and essential signaling pathways. In this context, chitosan (CT) has emerged as a promising biomaterial for advancing cancer treatment. With its unique combination of biocompatibility, biodegradability, and versatility, CT is gaining significant attention as a platform for developing innovative drug delivery systems. Recent research has highlighted the potential of CT-based materials to enhance drug efficacy by enabling controlled release, improving bioavailability, and facilitating targeted tumor delivery. Further modifications to CT, such as carboxymethylation, sulfation, and graft copolymerization, have significantly expanded its application in cancer therapy, allowing for more efficient encapsulation of chemotherapeutic agents, reducing systemic toxicity, and combating multidrug resistance. This review focuses on the latest developments (2021-2024) in CT-based materials for anticancer drug delivery, exploring their design principles, therapeutic mechanisms, and clinical applications. Additionally, the review discusses the challenges faced in translating these promising systems to clinical practice and highlights future strategies for optimizing CT-based therapies to revolutionize cancer treatment.

癌症仍然是全球最可怕的健康威胁之一,由于异常细胞不受控制的增殖和扩散,每年造成数百万人死亡。开发有效的抗癌疗法至关重要,因为抗癌药物针对关键的细胞机制,包括DNA复制、细胞凋亡和必要的信号通路。在此背景下,壳聚糖(CT)已成为一种有前途的生物材料,以推进癌症治疗。由于其独特的生物相容性、生物可降解性和多功能性,CT作为开发创新给药系统的平台受到了极大的关注。最近的研究强调了基于ct的材料通过控制释放、提高生物利用度和促进靶向肿瘤递送来增强药物疗效的潜力。CT的进一步改进,如羧甲基化、磺化和接枝共聚,极大地扩展了其在癌症治疗中的应用,允许更有效地包封化疗药物,降低全身毒性,并对抗多药耐药。本文综述了ct基抗癌药物传递材料的最新进展(2021-2024),探讨了其设计原理、治疗机制和临床应用。此外,该综述还讨论了将这些有前景的系统转化为临床实践所面临的挑战,并强调了优化基于ct的治疗以彻底改变癌症治疗的未来策略。
{"title":"Chitosan-Based Materials: A Comprehensive Review on Anticancer Drug Development.","authors":"Faris J Tayeb, Mohammed Fareed Felemban, Amal Adnan Ashour, Alaa Shafie","doi":"10.2174/0115734064388263250710083810","DOIUrl":"https://doi.org/10.2174/0115734064388263250710083810","url":null,"abstract":"<p><p>Cancer remains one of the most formidable global health threats, responsible for millions of deaths annually due to the uncontrolled proliferation and spread of abnormal cells. The development of effective anticancer therapies is crucial, as anticancer drugs target key cellular mechanisms, including DNA replication, apoptosis, and essential signaling pathways. In this context, chitosan (CT) has emerged as a promising biomaterial for advancing cancer treatment. With its unique combination of biocompatibility, biodegradability, and versatility, CT is gaining significant attention as a platform for developing innovative drug delivery systems. Recent research has highlighted the potential of CT-based materials to enhance drug efficacy by enabling controlled release, improving bioavailability, and facilitating targeted tumor delivery. Further modifications to CT, such as carboxymethylation, sulfation, and graft copolymerization, have significantly expanded its application in cancer therapy, allowing for more efficient encapsulation of chemotherapeutic agents, reducing systemic toxicity, and combating multidrug resistance. This review focuses on the latest developments (2021-2024) in CT-based materials for anticancer drug delivery, exploring their design principles, therapeutic mechanisms, and clinical applications. Additionally, the review discusses the challenges faced in translating these promising systems to clinical practice and highlights future strategies for optimizing CT-based therapies to revolutionize cancer treatment.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Molecular Docking Techniques: Transforming Perspectives in Distinct Drug Targeting and Drug Discovery Approaches. 分子对接技术的最新进展:不同药物靶向和药物发现方法的转变视角。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-21 DOI: 10.2174/0115734064384472250716144736
Rashid M Ansari, Radhika N Mundke, Yogeeta O Agrawal, Sameer N Goyal, Kartik T Nakhate, Sumit S Rathod

Introduction: Drug targeting and drug discovery methodologies are advancing rapidly due to recent developments in molecular docking techniques. Molecular docking forecasts the interactions between a small molecule, such as a potential medicine, and a target protein or receptor.

Objectives: This comprehensive review focuses on significant advances in molecular docking algorithms such as Vina, Glide, and AutoDock, including their enhanced accuracy and efficiency in predicting drug-target interactions. It also examines how novel features, such as fragment-based docking, covalent docking, and virtual screening, have expanded the significance of docking in modern pharmaceutical research.

Methods: The literature search was carried out by employing search engines such as PubMed and Google Scholar with keywords such as Molecular Docking, Lead-Optimization, Protein Flexibility, Fragment-Based Docking, Covalent Docking, and Virtual Screening.

Results: This present state-of-the-art review highlights recent advances in various docking methodologies and their significant applications in drug discovery, while also discussing the scoring functions of some well-established studies. Furthermore, by predicting the interactions between putative medications and protein residues involved in the creation of covalent bonds, covalent docking provides new opportunities for targeting difficult drug-resistant mutations. The efficiency and precision of these simulations have been increased by improved sampling techniques and sophisticated algorithms, enabling the investigation of conformational changes and protein flexibility throughout the drug-binding process.

Conclusion: These approaches may hasten the course of emerging new remedies, increase the precision of hit-finding, and make it easier to find cutting-edge treatments for a variety of diseases. Molecular docking alone is insufficient to ensure the safety and efficacy of a pharmacological agent for commercialization. While it predicts binding affinity and interaction, it does not account for pharmacokinetics, toxicity, off-target effects, or in vivo behavior. Therefore, experimental validation through MD simulation, ADMET, in vitro, in vivo, and clinical studies is essential.

由于分子对接技术的发展,药物靶向和药物发现方法正在迅速发展。分子对接预测小分子(如潜在药物)与目标蛋白或受体之间的相互作用。目的:本文综述了分子对接算法的重大进展,如Vina、Glide和AutoDock,包括它们在预测药物-靶标相互作用方面提高的准确性和效率。它还探讨了诸如基于片段的对接、共价对接和虚拟筛选等新特性如何扩大了对接在现代药物研究中的意义。方法:利用PubMed、谷歌Scholar等搜索引擎进行文献检索,关键词为分子对接、Lead-Optimization、Protein Flexibility、Fragment-Based对接、Covalent对接、Virtual Screening。结果:这篇最新的综述强调了各种对接方法的最新进展及其在药物发现中的重要应用,同时也讨论了一些成熟研究的评分功能。此外,通过预测推定药物与参与共价键形成的蛋白质残基之间的相互作用,共价对接为靶向困难的耐药突变提供了新的机会。通过改进的采样技术和复杂的算法,这些模拟的效率和精度得到了提高,从而能够研究整个药物结合过程中的构象变化和蛋白质灵活性。结论:这些方法可能会加速新疗法的出现,提高发现靶点的精度,并使寻找各种疾病的尖端治疗方法变得更容易。单靠分子对接不足以保证药物商业化的安全性和有效性。虽然它预测结合亲和力和相互作用,但它不能解释药代动力学、毒性、脱靶效应或体内行为。因此,通过MD模拟、ADMET、体外、体内和临床研究进行实验验证是必不可少的。
{"title":"Recent Advances in Molecular Docking Techniques: Transforming Perspectives in Distinct Drug Targeting and Drug Discovery Approaches.","authors":"Rashid M Ansari, Radhika N Mundke, Yogeeta O Agrawal, Sameer N Goyal, Kartik T Nakhate, Sumit S Rathod","doi":"10.2174/0115734064384472250716144736","DOIUrl":"https://doi.org/10.2174/0115734064384472250716144736","url":null,"abstract":"<p><strong>Introduction: </strong>Drug targeting and drug discovery methodologies are advancing rapidly due to recent developments in molecular docking techniques. Molecular docking forecasts the interactions between a small molecule, such as a potential medicine, and a target protein or receptor.</p><p><strong>Objectives: </strong>This comprehensive review focuses on significant advances in molecular docking algorithms such as Vina, Glide, and AutoDock, including their enhanced accuracy and efficiency in predicting drug-target interactions. It also examines how novel features, such as fragment-based docking, covalent docking, and virtual screening, have expanded the significance of docking in modern pharmaceutical research.</p><p><strong>Methods: </strong>The literature search was carried out by employing search engines such as PubMed and Google Scholar with keywords such as Molecular Docking, Lead-Optimization, Protein Flexibility, Fragment-Based Docking, Covalent Docking, and Virtual Screening.</p><p><strong>Results: </strong>This present state-of-the-art review highlights recent advances in various docking methodologies and their significant applications in drug discovery, while also discussing the scoring functions of some well-established studies. Furthermore, by predicting the interactions between putative medications and protein residues involved in the creation of covalent bonds, covalent docking provides new opportunities for targeting difficult drug-resistant mutations. The efficiency and precision of these simulations have been increased by improved sampling techniques and sophisticated algorithms, enabling the investigation of conformational changes and protein flexibility throughout the drug-binding process.</p><p><strong>Conclusion: </strong>These approaches may hasten the course of emerging new remedies, increase the precision of hit-finding, and make it easier to find cutting-edge treatments for a variety of diseases. Molecular docking alone is insufficient to ensure the safety and efficacy of a pharmacological agent for commercialization. While it predicts binding affinity and interaction, it does not account for pharmacokinetics, toxicity, off-target effects, or in vivo behavior. Therefore, experimental validation through MD simulation, ADMET, in vitro, in vivo, and clinical studies is essential.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Search for New Amidrazone Derivatives Containing 4-Oxybut-2-enoic Acid Moiety as Antibacterial Agents. 含4-氧丁-2-烯酸的新型氨基腙类抗菌药物的研究。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-15 DOI: 10.2174/0115734064396576250706091217
Renata Paprocka, Monika Przybysz, Kamila Pośpieszyńska, Ashley Chepkoech, Dominika Jagleniec, Antoni Godlewski, Karolina Korczak, Małgorzata Wiese-Szadkowska, Jolanta Kutkowska

Introduction: Bacterial diseases pose a significant challenge to modern medicine due to the rapid development of resistance by bacterial strains and the global migration of people, which facilitates the transmission of these diseases. Therefore, there is a need to develop new strategies to combat microorganisms and newer substances that could be used as antibiotics.

Methods: Six new derivatives, 2a-2f, containing a 4-oxybut-2-enoic acid moiety, were obtained by reacting amidrazones with maleic anhydride. The antimicrobial potency of compounds 2a-2f was studied using the microdilution method against the following bacterial strains: Escherichia coli, Yersinia enterocolitica, Pseudomonas aeruginosa, Staphylococcus aureus, Micrococcus luteus, Enterococcus faecalis, Gordonia rubripertincta, Mycobacterium smegmatis, and the fungal strain Candida albicans. Their antiproliferative activity was tested in cultures of human peripheral blood mononuclear cells stimulated with phytohemagglutinin. The bioavailability parameters of new compounds were predicted using Molinspiration software.

Results: Derivatives 2a-2c showed the strongest antibacterial activity, especially against Yersinia enterocolitica and Micrococcus luteus. Compounds 2d-2f inhibited the growth of Gordonia rubripertincta. Compounds 2a-2f exhibited low antiproliferative activity towards human peripheral blood mononuclear cells. However, it is necessary to evaluate whether all compounds are well absorbed after oral administration.

Discussion: The most promising antibacterial activity was demonstrated by derivatives possessing a 2-pyridyl substituent at the R1 position (2a-2c) or a phenyl ring at the R2 position (2a, 2f).

Conclusion: Compound 2a demonstrated the highest antibacterial activity and selectivity in inhibiting the growth of Y. enterocolitica. Additionally, it exhibited low toxicity to human lymphocytes and demonstrated favorable bioavailability parameters. Therefore, its structure can be used as a starting point for designing new antimicrobials, such as targeted therapies for yersiniosis, beyond traditional antibiotics.

导言:细菌性疾病对现代医学提出了重大挑战,因为细菌菌株的耐药性迅速发展,以及全球人口的迁移,促进了这些疾病的传播。因此,有必要开发新的策略来对抗微生物和可用作抗生素的新物质。方法:通过偕胺酮与顺丁烯酸酐反应,得到6个含有4-羟丁-2-烯酸片段的新衍生物2a-2f。采用微量稀释法研究化合物2a-2f对大肠埃希菌、小肠结肠炎耶尔森菌、铜绿假单胞菌、金黄色葡萄球菌、黄体微球菌、粪肠球菌、红带戈登菌、耻垢分枝杆菌和白色念珠菌的抑菌效果。在植物血凝素刺激的人外周血单个核细胞培养中检测了它们的抗增殖活性。利用Molinspiration软件预测新化合物的生物利用度参数。结果:衍生物2a-2c的抑菌活性最强,对小肠结肠炎耶尔森菌和黄体微球菌的抑菌活性最强。化合物2d-2f对红毛戈登的生长有抑制作用。化合物2a-2f对人外周血单核细胞表现出较低的抗增殖活性。然而,有必要评估口服后是否所有化合物都能很好地吸收。讨论:最有希望的抗菌活性是衍生物在R1位置(2a-2c)具有2-吡啶取代基或在R2位置(2a, 2f)具有苯基环。结论:化合物2a对小肠结肠炎菌的抑菌活性和抑制选择性最高。此外,它对人类淋巴细胞具有低毒性,并具有良好的生物利用度参数。因此,它的结构可以作为设计新的抗菌素的起点,如针对耶尔森菌病的靶向治疗,而不是传统的抗生素。
{"title":"A Search for New Amidrazone Derivatives Containing 4-Oxybut-2-enoic Acid Moiety as Antibacterial Agents.","authors":"Renata Paprocka, Monika Przybysz, Kamila Pośpieszyńska, Ashley Chepkoech, Dominika Jagleniec, Antoni Godlewski, Karolina Korczak, Małgorzata Wiese-Szadkowska, Jolanta Kutkowska","doi":"10.2174/0115734064396576250706091217","DOIUrl":"https://doi.org/10.2174/0115734064396576250706091217","url":null,"abstract":"<p><strong>Introduction: </strong>Bacterial diseases pose a significant challenge to modern medicine due to the rapid development of resistance by bacterial strains and the global migration of people, which facilitates the transmission of these diseases. Therefore, there is a need to develop new strategies to combat microorganisms and newer substances that could be used as antibiotics.</p><p><strong>Methods: </strong>Six new derivatives, <b>2a-2f</b>, containing a 4-oxybut-2-enoic acid moiety, were obtained by reacting amidrazones with maleic anhydride. The antimicrobial potency of compounds <b>2a-2f</b> was studied using the microdilution method against the following bacterial strains: <i>Escherichia coli, Yersinia enterocolitica, Pseudomonas aeruginosa, Staphylococcus aureus, Micrococcus luteus, Enterococcus faecalis, Gordonia rubripertincta, Mycobacterium smegmatis</i>, and the fungal strain <i>Candida albicans</i>. Their antiproliferative activity was tested in cultures of human peripheral blood mononuclear cells stimulated with phytohemagglutinin. The bioavailability parameters of new compounds were predicted using Molinspiration software.</p><p><strong>Results: </strong>Derivatives <b>2a-2c</b> showed the strongest antibacterial activity, especially against <i>Yersinia enterocolitica</i> and <i>Micrococcus luteus</i>. Compounds <b>2d-2f</b> inhibited the growth of <i>Gordonia rubripertincta</i>. Compounds <b>2a-2f</b> exhibited low antiproliferative activity towards human peripheral blood mononuclear cells. However, it is necessary to evaluate whether all compounds are well absorbed after oral administration.</p><p><strong>Discussion: </strong>The most promising antibacterial activity was demonstrated by derivatives possessing a 2-pyridyl substituent at the R1 position (<b>2a-2c</b>) or a phenyl ring at the R<sup>2</sup> position (2a, 2f).</p><p><strong>Conclusion: </strong>Compound <b>2a</b> demonstrated the highest antibacterial activity and selectivity in inhibiting the growth of <i>Y. enterocolitica</i>. Additionally, it exhibited low toxicity to human lymphocytes and demonstrated favorable bioavailability parameters. Therefore, its structure can be used as a starting point for designing new antimicrobials, such as targeted therapies for yersiniosis, beyond traditional antibiotics.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antioxidant and Cytotoxic Activity of the Aporphine Alkaloid (Boldine) Against DMH-induced Colorectal Carcinogenesis in Wistar Rats: An In silico, In vitro, and In vivo study. 阿波啡生物碱(Boldine)抗dmh诱导的Wistar大鼠结直肠癌的抗氧化和细胞毒活性:一项硅、体外和体内研究。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-03 DOI: 10.2174/0115734064358287250613065507
Monu Kumar Kashyap, Akash Ved, Pranay Wal, Akhand Pratap Singh
<p><strong>Objective: </strong>The objective of this study is to investigate the role of the aporphine alkaloid boldine as a potential inhibitor of specific protein targets involved in colorectal cancer, using <i>in silico</i> docking and molecular dynamics simulation studies, and to evaluate its therapeutic potential in modulating the pathological progression of colorectal cancer. In this study, we evaluated the antioxidant and cytotoxic effects of boldine using <i>in vitro</i> and <i>in vivo</i> methods.</p><p><strong>Methods: </strong>The 2-dimensional structure of boldine was retrieved from the PubChem database. Its interactions with colorectal cancer target proteins were analyzed using structures obtained from the RCSB Protein Data Bank (https://www.rcsb.org/), which provides the crystal structures of tubulin (PDB ID: 1Z2B), human NF- κB (1A3Q), human interleukin-2 (1M47), and EGFR-kinase. Molecular docking was then performed using Schrödinger software. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate Boldine's binding affinity and stability with colorectal cancer protein targets. On the Growmac platform, we performed the molecular simulation, and the simulation was only done with the highest docking score. Additionally, molecular dynamics was performed for 100 ns. Boldine was added to the colorectal cancer cell line (HCT116) at different doses, and the cytotoxic effects of the treatment were evaluated using cell viability assays. Furthermore, Boldine's capacity to scavenge reactive oxygen species (ROS) and modify the oxidative stress assay <i>in vitro</i> was used to assess its antioxidant capability. Boldine's in vivo anticancer effectiveness was examined using DMH-induced colorectal cancer in Wistar Rats. After Boldine was administered (100mg/Kg), Tumour progression, histological alteration, and oxidative stress markers were evaluated. The study aimed to ascertain how boldine affects tumor growth in DMH-inducedDMH colorectal carcinogenesis.</p><p><strong>Results: </strong>Molecular docking revealed favorable binding interactions between boldine and key targets implicated in colorectal cancer. The <i>in silico</i> data supported the hypothesis that boldine modulates essential pathways associated with cancer development. Boldine exhibited a dose-dependent reduction in colorectal cancer cell viability, indicating potential cytotoxic effects. Furthermore, boldine demonstrated antioxidant properties by effectively scavenging reactive oxygen species (ROS) and modulating oxidative stress markers in vitro. In animal models, boldine administration resulted in a significant reduction in tumor growth. Histopathological examination revealed favorable changes in tumor morphology. Additionally, boldine demonstrated antioxidant effects in vivo by modulating oxidative stress markers.</p><p><strong>Conclusion: </strong>According to this extensive study performed <i>in silico</i>, <i>in vitro</i>, and <i>in vivo</i>, bol
目的:本研究的目的是通过硅对接和分子动力学模拟研究,探讨阿啡类生物碱boldine作为结直肠癌特异性蛋白靶点的潜在抑制剂的作用,并评估其在调节结直肠癌病理进展中的治疗潜力。在本研究中,我们通过体外和体内方法评价了boldine的抗氧化和细胞毒作用。方法:从PubChem数据库中检索boldine的二维结构。利用RCSB蛋白数据库(https://www.rcsb.org/)获得的结构分析其与结直肠癌靶蛋白的相互作用,该数据库提供了微管蛋白(PDB ID: 1Z2B)、人NF- κB (1A3Q)、人白细胞介素-2 (1M47)和egfr -激酶的晶体结构。然后使用Schrödinger软件进行分子对接。通过分子对接和分子动力学(MD)模拟来评估Boldine与结直肠癌蛋白靶点的结合亲和力和稳定性。在Growmac平台上,我们进行了分子模拟,模拟只在对接得分最高的情况下进行。在100 ns的时间内进行分子动力学分析。将不同剂量的Boldine添加到结直肠癌细胞系(HCT116)中,并通过细胞活力测定来评估治疗的细胞毒性作用。此外,我们还利用Boldine清除活性氧(ROS)和修饰氧化应激的能力来评估其体外抗氧化能力。采用dmh诱导的Wistar大鼠结直肠癌,研究了Boldine的体内抗癌效果。给予Boldine (100mg/Kg)后,评估肿瘤进展、组织学改变和氧化应激标志物。该研究旨在确定在dmh诱导的dmh结直肠癌中,boldine如何影响肿瘤生长。结果:分子对接揭示了boldine与结直肠癌相关的关键靶点之间良好的结合相互作用。计算机数据支持了boldine调节与癌症发展相关的基本途径的假设。Boldine在结肠直肠癌细胞活力中表现出剂量依赖性降低,表明潜在的细胞毒性作用。此外,boldine通过在体外有效清除活性氧(ROS)和调节氧化应激标志物显示出抗氧化特性。在动物模型中,给药可显著降低肿瘤生长。组织病理学检查显示肿瘤形态发生了良好的变化。此外,boldine通过调节氧化应激标志物在体内表现出抗氧化作用。结论:根据这项在硅、体外和体内进行的广泛研究,boldine可能通过其抗氧化和细胞毒性来预防结直肠癌。这些结果鼓励了更多的研究,将泊定作为治疗结直肠癌的可行选择。它是成功地完成的,我们可以说,博林是一个有价值的补充,以结直肠癌的治疗选择。
{"title":"Antioxidant and Cytotoxic Activity of the Aporphine Alkaloid (Boldine) Against DMH-induced Colorectal Carcinogenesis in Wistar Rats: An <i>In silico, In vitro</i>, and <i>In vivo</i> study.","authors":"Monu Kumar Kashyap, Akash Ved, Pranay Wal, Akhand Pratap Singh","doi":"10.2174/0115734064358287250613065507","DOIUrl":"https://doi.org/10.2174/0115734064358287250613065507","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The objective of this study is to investigate the role of the aporphine alkaloid boldine as a potential inhibitor of specific protein targets involved in colorectal cancer, using &lt;i&gt;in silico&lt;/i&gt; docking and molecular dynamics simulation studies, and to evaluate its therapeutic potential in modulating the pathological progression of colorectal cancer. In this study, we evaluated the antioxidant and cytotoxic effects of boldine using &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; methods.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The 2-dimensional structure of boldine was retrieved from the PubChem database. Its interactions with colorectal cancer target proteins were analyzed using structures obtained from the RCSB Protein Data Bank (https://www.rcsb.org/), which provides the crystal structures of tubulin (PDB ID: 1Z2B), human NF- κB (1A3Q), human interleukin-2 (1M47), and EGFR-kinase. Molecular docking was then performed using Schrödinger software. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate Boldine's binding affinity and stability with colorectal cancer protein targets. On the Growmac platform, we performed the molecular simulation, and the simulation was only done with the highest docking score. Additionally, molecular dynamics was performed for 100 ns. Boldine was added to the colorectal cancer cell line (HCT116) at different doses, and the cytotoxic effects of the treatment were evaluated using cell viability assays. Furthermore, Boldine's capacity to scavenge reactive oxygen species (ROS) and modify the oxidative stress assay &lt;i&gt;in vitro&lt;/i&gt; was used to assess its antioxidant capability. Boldine's in vivo anticancer effectiveness was examined using DMH-induced colorectal cancer in Wistar Rats. After Boldine was administered (100mg/Kg), Tumour progression, histological alteration, and oxidative stress markers were evaluated. The study aimed to ascertain how boldine affects tumor growth in DMH-inducedDMH colorectal carcinogenesis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Molecular docking revealed favorable binding interactions between boldine and key targets implicated in colorectal cancer. The &lt;i&gt;in silico&lt;/i&gt; data supported the hypothesis that boldine modulates essential pathways associated with cancer development. Boldine exhibited a dose-dependent reduction in colorectal cancer cell viability, indicating potential cytotoxic effects. Furthermore, boldine demonstrated antioxidant properties by effectively scavenging reactive oxygen species (ROS) and modulating oxidative stress markers in vitro. In animal models, boldine administration resulted in a significant reduction in tumor growth. Histopathological examination revealed favorable changes in tumor morphology. Additionally, boldine demonstrated antioxidant effects in vivo by modulating oxidative stress markers.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;According to this extensive study performed &lt;i&gt;in silico&lt;/i&gt;, &lt;i&gt;in vitro&lt;/i&gt;, and &lt;i&gt;in vivo&lt;/i&gt;, bol","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Syntheses and Identification of New Dithiophosphinic Acid Complexes and Their Potential as Photodynamic Agents in Cancer Therapy. 新型二硫代膦酸配合物的合成、鉴定及其在癌症治疗中的光动力作用。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-03 DOI: 10.2174/0115734064382461250618113452
Kübra A Coşkun, Elif Bulat, Hamza Yılmaz, Ertuğrul Gazi Sağlam, Lutfi Tutar, Fayyaz Ur Rehman, Yusuf Tutar

Background: The photo-efficacy of oncological phototherapy for both internal and external tumors is encouraging. When light and photochemotherapeutic drugs are applied together, precise cancer targeting, minimal invasiveness, and innovative modes of action are made possible. Current developments in photoactive compounds and new light sources are promising for further advancement.

Objective: When designing photosensitizers, metal complexes may be advantageous since the metal can enhance stability and photocytotoxicity while facilitating their localization and quantification. The absorption spectra of photosensitizers limit their excitation wavelengths, which impact light tissue penetration that differs in various organs. Since longer wavelength light penetrates deeper, PDT is typically carried out at wavelengths greater than 620 nm. Additionally, employing lower intensity (>4-8 J/cm2) energy can greatly lessen the pain and discomfort induced by red-light PDT.

Methods: Low-level laser therapy exposure was used to assess the dithiophosphinic acid complexes' photodynamic treatment efficacy in MCF-7 cells. Following the administration of the complexes at concentrations within IC50 values, red light (4 J, 780 nm) was applied to the cells. Afterward, MCF-7 cells were cultured for 24 hours to evaluate the photodynamic effects of the compounds on cancer cells. Cell viability was assessed using the XTT assay kit.

Results: DTPA complexes have shown effectiveness as photodynamic agents in cancer therapy, with Ni(II) and Ni(II)-pyridine complexes demonstrating significant cytotoxicity against cancer cells.

Conclusion: Light-activated cancer cell therapies are promising, and the synthesized complexes affect the cell cycle and apoptosis-regulating proteins. The compounds can be employed as anticancer agents and a fine starting template for photodynamic drug design.

背景:肿瘤光疗治疗内外肿瘤的光效令人鼓舞。当光和光化学治疗药物一起应用时,精确的癌症靶向,最小的侵入性和创新的作用模式成为可能。目前在光活性化合物和新光源方面的进展有进一步发展的希望。目的:在设计光敏剂时,金属配合物可能具有优势,因为金属配合物可以增强光敏剂的稳定性和光细胞毒性,同时易于定位和定量。光敏剂的吸收光谱限制了其激发波长,这影响了光组织在不同器官中的穿透性。由于波长较长的光穿透更深,PDT通常在波长大于620nm的情况下进行。此外,采用较低的能量强度(>4-8 J/cm2)可以大大减轻红光PDT引起的疼痛和不适。方法:采用低强度激光照射法评价二硫代膦酸配合物对MCF-7细胞的光动力治疗效果。在IC50浓度范围内给药后,对细胞施加红光(4 J, 780 nm)。随后,培养MCF-7细胞24小时,以评估化合物对癌细胞的光动力学作用。采用XTT检测试剂盒检测细胞活力。结果:DTPA配合物作为光动力药物在癌症治疗中显示出有效性,Ni(II)和Ni(II)-吡啶配合物对癌细胞显示出显著的细胞毒性。结论:光激活肿瘤细胞的治疗前景广阔,其合成的复合物影响细胞周期和凋亡调节蛋白。这些化合物可以用作抗癌剂和光动力药物设计的良好起始模板。
{"title":"Syntheses and Identification of New Dithiophosphinic Acid Complexes and Their Potential as Photodynamic Agents in Cancer Therapy.","authors":"Kübra A Coşkun, Elif Bulat, Hamza Yılmaz, Ertuğrul Gazi Sağlam, Lutfi Tutar, Fayyaz Ur Rehman, Yusuf Tutar","doi":"10.2174/0115734064382461250618113452","DOIUrl":"https://doi.org/10.2174/0115734064382461250618113452","url":null,"abstract":"<p><strong>Background: </strong>The photo-efficacy of oncological phototherapy for both internal and external tumors is encouraging. When light and photochemotherapeutic drugs are applied together, precise cancer targeting, minimal invasiveness, and innovative modes of action are made possible. Current developments in photoactive compounds and new light sources are promising for further advancement.</p><p><strong>Objective: </strong>When designing photosensitizers, metal complexes may be advantageous since the metal can enhance stability and photocytotoxicity while facilitating their localization and quantification. The absorption spectra of photosensitizers limit their excitation wavelengths, which impact light tissue penetration that differs in various organs. Since longer wavelength light penetrates deeper, PDT is typically carried out at wavelengths greater than 620 nm. Additionally, employing lower intensity (>4-8 J/cm<sup>2</sup>) energy can greatly lessen the pain and discomfort induced by red-light PDT.</p><p><strong>Methods: </strong>Low-level laser therapy exposure was used to assess the dithiophosphinic acid complexes' photodynamic treatment efficacy in MCF-7 cells. Following the administration of the complexes at concentrations within IC<sub>50</sub> values, red light (4 J, 780 nm) was applied to the cells. Afterward, MCF-7 cells were cultured for 24 hours to evaluate the photodynamic effects of the compounds on cancer cells. Cell viability was assessed using the XTT assay kit.</p><p><strong>Results: </strong>DTPA complexes have shown effectiveness as photodynamic agents in cancer therapy, with Ni(II) and Ni(II)-pyridine complexes demonstrating significant cytotoxicity against cancer cells.</p><p><strong>Conclusion: </strong>Light-activated cancer cell therapies are promising, and the synthesized complexes affect the cell cycle and apoptosis-regulating proteins. The compounds can be employed as anticancer agents and a fine starting template for photodynamic drug design.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising Flavone Derivatives as Anticancer Agents. 黄酮衍生物作为抗癌剂的前景。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-07-02 DOI: 10.2174/0115734064384513250624043626
Vishakha A Patil, Kalyani R Thombre, Krishna Radheshyam Gupta, Milind Janrao Umekar

Currently, the main focus of anticancer drug development and research is to develop anticancer treatment strategies that are both less harmful and more effective. Flavones, a subclass of flavonoids, have shown great promise in the advancement of anticancer drugs because of their strong bioactive properties. Fruits, vegetables, and medicinal plants are abundant sources of these naturally occurring compounds, which have a variety of biological activities such as anti-inflammatory, anti-cancer, and antioxidant properties. Flavones and their derivatives have attracted a lot of attention recently because of their potential to modify significant molecular pathways that are involved in the growth, apoptosis, angiogenesis, and metastasis of cancer cells. The objective of this review is to present a thorough analysis of the chemical makeup of flavone as an anticancer agent. By altering the flavone scaffold's structure, there are beneficial chances to improve its therapeutic qualities, such as its potency, selectivity, and pharmacokinetics. The structural alterations of flavone derivatives that improve their anticancer potency and selectivity are highlighted. Most noteworthy, flavones offer a promising framework for the creation of new anticancer medications, and further research into them may help create more potent and focused cancer treatments.

目前,抗癌药物开发和研究的主要焦点是开发危害更小、更有效的抗癌治疗策略。黄酮类化合物是黄酮类化合物的一个亚类,由于其具有很强的生物活性,在抗癌药物的发展中显示出很大的前景。水果、蔬菜和药用植物是这些天然化合物的丰富来源,它们具有多种生物活性,如抗炎、抗癌和抗氧化特性。近年来,黄酮及其衍生物引起了人们的广泛关注,因为它们有可能改变与癌细胞生长、凋亡、血管生成和转移有关的重要分子途径。本文综述的目的是全面分析作为抗癌剂的黄酮的化学组成。通过改变黄酮支架的结构,有机会改善其治疗质量,如其效力、选择性和药代动力学。强调了黄酮衍生物的结构改变,提高了其抗癌效力和选择性。最值得注意的是,黄酮为创造新的抗癌药物提供了一个有希望的框架,对它们的进一步研究可能有助于创造更有效、更有针对性的癌症治疗方法。
{"title":"Promising Flavone Derivatives as Anticancer Agents.","authors":"Vishakha A Patil, Kalyani R Thombre, Krishna Radheshyam Gupta, Milind Janrao Umekar","doi":"10.2174/0115734064384513250624043626","DOIUrl":"https://doi.org/10.2174/0115734064384513250624043626","url":null,"abstract":"<p><p><p> Currently, the main focus of anticancer drug development and research is to develop anticancer treatment strategies that are both less harmful and more effective. Flavones, a subclass of flavonoids, have shown great promise in the advancement of anticancer drugs because of their strong bioactive properties. Fruits, vegetables, and medicinal plants are abundant sources of these naturally occurring compounds, which have a variety of biological activities such as anti-inflammatory, anti-cancer, and antioxidant properties. Flavones and their derivatives have attracted a lot of attention recently because of their potential to modify significant molecular pathways that are involved in the growth, apoptosis, angiogenesis, and metastasis of cancer cells. The objective of this review is to present a thorough analysis of the chemical makeup of flavone as an anticancer agent. By altering the flavone scaffold's structure, there are beneficial chances to improve its therapeutic qualities, such as its potency, selectivity, and pharmacokinetics. The structural alterations of flavone derivatives that improve their anticancer potency and selectivity are highlighted. Most noteworthy, flavones offer a promising framework for the creation of new anticancer medications, and further research into them may help create more potent and focused cancer treatments.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Cholinesterase Inhibitory Potential of Azines Bearing a 4,4-bisdimethylaminobenzophenone Scaffold: An Experimental and Computational Approach. 探索含4,4-二二甲氨基苯甲酮支架的氮嘧啶的胆碱酯酶抑制潜能:实验和计算方法。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-06-24 DOI: 10.2174/0115734064375363250620173232
Ghulam Ahad, Aftab Alam, Ahmed A Elhenawy, Imtiaz Ahmad, Fayaz Ur Rahman, Munir Ur Rehman, Abid Ali, Abdullah F AlAsmari, Fawaz Alasmari, Momin Khan

Background: Acetyl and butyrylcholinesterase are significant enzymes involved in neurological diseases, and the development of more effective inhibitors is crucial for beneficial interference.

Objective: To evaluate the cholinesterase inhibition effect of the synthetic bis-Schiff base compounds and discover the electronic properties as well as binding affinities through computational studies.

Methods: The compounds were synthesized and screened against acetyl and butyrylcholinesterase inhibitory activities in-vitro, while DFT analysis and molecular docking studies were performed for the product compounds.

Results: Seven compounds, including 2a, 2b, 2e, 2c, 2d, 2i, and 2j, exhibited excellent AChE activity, while nine compounds showed potent BChE inhibition compared to galantamine (IC50 = 156.4 ± 1.13 μM). Furthermore, the recent study on molecules 2a-e has provided valuable insights into their mechanism of action as inhibitors of the enzyme ChE, which is crucial for understanding how to regulate this enzyme's activity. Through the use of Time-Dependent Density Functional Theory (TD-DFT), the electronic characteristics of these molecules were meticulously examined, revealing that the Highest Occupied Molecular Orbitals (HOMO) are extensively delocalized across the molecular frameworks of the most active 2a-e compounds. This suggests a significant degree of electron delocalization, which is often associated with chemical reactivity and stability. In comparison to standard galantamine, these compounds demonstrate a lower electrophilicity index, which is indicative of their increased biological efficacy and lower toxicity.

Conclusion: These derivatives showed excellent AChE and BChE activities with favorable electronic properties and superior binding affinities, highlighting their potential as effective inhibitors as therapeutic agents.

背景:乙酰和丁基胆碱酯酶是神经系统疾病的重要酶,开发更有效的抑制剂对有益干预至关重要。目的:评价合成的双希夫碱化合物对胆碱酯酶的抑制作用,并通过计算研究发现其电子性质和结合亲和力。方法:对合成的化合物进行体外乙酰胆碱酯酶和丁基胆碱酯酶抑制活性筛选,并对产物化合物进行DFT分析和分子对接研究。结果:7个化合物(2a、2b、2e、2c、2d、2i和2j)表现出较好的AChE活性,9个化合物对BChE有较强的抑制作用(IC50 = 156.4±1.13 μM)。此外,最近对2a-e分子的研究为其作为ChE酶抑制剂的作用机制提供了有价值的见解,这对于理解如何调节该酶的活性至关重要。通过使用时间依赖密度泛函理论(TD-DFT),仔细检查了这些分子的电子特性,揭示了最高已占据分子轨道(HOMO)在最活跃的2a-e化合物的分子框架中广泛地离域。这表明了电子离域的显著程度,这往往与化学反应性和稳定性有关。与标准加兰他明相比,这些化合物的亲电性指数较低,这表明它们的生物功效更高,毒性更低。结论:这些衍生物具有良好的AChE和BChE活性,具有良好的电子性质和良好的结合亲和力,具有作为有效抑制剂和治疗剂的潜力。
{"title":"Exploring the Cholinesterase Inhibitory Potential of Azines Bearing a 4,4-bisdimethylaminobenzophenone Scaffold: An Experimental and Computational Approach.","authors":"Ghulam Ahad, Aftab Alam, Ahmed A Elhenawy, Imtiaz Ahmad, Fayaz Ur Rahman, Munir Ur Rehman, Abid Ali, Abdullah F AlAsmari, Fawaz Alasmari, Momin Khan","doi":"10.2174/0115734064375363250620173232","DOIUrl":"https://doi.org/10.2174/0115734064375363250620173232","url":null,"abstract":"<p><strong>Background: </strong>Acetyl and butyrylcholinesterase are significant enzymes involved in neurological diseases, and the development of more effective inhibitors is crucial for beneficial interference.</p><p><strong>Objective: </strong>To evaluate the cholinesterase inhibition effect of the synthetic bis-Schiff base compounds and discover the electronic properties as well as binding affinities through computational studies.</p><p><strong>Methods: </strong>The compounds were synthesized and screened against acetyl and butyrylcholinesterase inhibitory activities in-vitro, while DFT analysis and molecular docking studies were performed for the product compounds.</p><p><strong>Results: </strong>Seven compounds, including <b>2a, 2b, 2e, 2c, 2d, 2i</b>, and <b>2j</b>, exhibited excellent AChE activity, while nine compounds showed potent BChE inhibition compared to galantamine (IC50 = 156.4 ± 1.13 μM). Furthermore, the recent study on molecules 2a-e has provided valuable insights into their mechanism of action as inhibitors of the enzyme ChE, which is crucial for understanding how to regulate this enzyme's activity. Through the use of Time-Dependent Density Functional Theory (TD-DFT), the electronic characteristics of these molecules were meticulously examined, revealing that the Highest Occupied Molecular Orbitals (HOMO) are extensively delocalized across the molecular frameworks of the most active <b>2a-e</b> compounds. This suggests a significant degree of electron delocalization, which is often associated with chemical reactivity and stability. In comparison to standard galantamine, these compounds demonstrate a lower electrophilicity index, which is indicative of their increased biological efficacy and lower toxicity.</p><p><strong>Conclusion: </strong>These derivatives showed excellent AChE and BChE activities with favorable electronic properties and superior binding affinities, highlighting their potential as effective inhibitors as therapeutic agents.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimized Strategies for the Synthesis and Structure-Activity Relationship of Imidazole as an Antiepileptic Drug. 抗癫痫药物咪唑的合成及构效关系优化。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-06-10 DOI: 10.2174/0115734064377779250529172030
Saloni Mangal, Salahuddin, Avijit Mazumder, Rajnish Kumar, Sapna Rani, Vimal Datt, Mohamed Jawed Ahsan, Mohammad Shahar Yar

Imidazole is believed to be a highly multifunctional compound in the medicinal and biological sectors. This literature focuses on information about the synthesis and anticonvulsant activity presented by the imidazole nucleus. Epilepsy is a chronic brain disorder including multiple seizures and brain cell abnormalities. Due to its old and less effective treatment, with the increase in the number of patients suffering from epilepsy, researchers need to concentrate on the emergence of finding new treatments for epilepsy. Imidazole-containing analogs are found to be significant in the field of medicinal chemistry and the treatment for epilepsy. These studies prompted us to synthesize and provide insights into developing new imidazole-bearing antiepileptic drugs.

咪唑被认为是一种在医药和生物领域具有高度多功能的化合物。本文献主要介绍咪唑核的合成和抗惊厥活性。癫痫是一种慢性脑部疾病,包括多次发作和脑细胞异常。由于其治疗方法陈旧且效果不佳,随着癫痫患者数量的增加,研究人员需要集中精力寻找新的癫痫治疗方法的出现。含咪唑类似物在药物化学和癫痫治疗领域具有重要意义。这些研究促使我们合成并为开发新的含咪唑抗癫痫药物提供见解。
{"title":"Optimized Strategies for the Synthesis and Structure-Activity Relationship of Imidazole as an Antiepileptic Drug.","authors":"Saloni Mangal, Salahuddin, Avijit Mazumder, Rajnish Kumar, Sapna Rani, Vimal Datt, Mohamed Jawed Ahsan, Mohammad Shahar Yar","doi":"10.2174/0115734064377779250529172030","DOIUrl":"https://doi.org/10.2174/0115734064377779250529172030","url":null,"abstract":"<p><p>Imidazole is believed to be a highly multifunctional compound in the medicinal and biological sectors. This literature focuses on information about the synthesis and anticonvulsant activity presented by the imidazole nucleus. Epilepsy is a chronic brain disorder including multiple seizures and brain cell abnormalities. Due to its old and less effective treatment, with the increase in the number of patients suffering from epilepsy, researchers need to concentrate on the emergence of finding new treatments for epilepsy. Imidazole-containing analogs are found to be significant in the field of medicinal chemistry and the treatment for epilepsy. These studies prompted us to synthesize and provide insights into developing new imidazole-bearing antiepileptic drugs.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Pyrrolopyrimidines as Inhibitors of CLK4 and HER2: Targeting Promising Anticancer Pathways. 新型吡咯嘧啶作为CLK4和HER2抑制剂:靶向有希望的抗癌途径
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-06-03 DOI: 10.2174/0115734064386606250410111952
Jonathan Gries, Frank Totzke, Andreas Hilgeroth

Background: Dysregulated cellular signaling pathways involving protein kinases are critically implicated in cancer development. Consequently, protein kinases have emerged as key targets for novel anticancer therapies. A range of kinase inhibitors, including small molecules and monoclonal antibodies, has been developed. Although early strategies focused on achieving high specificity to minimize adverse effects, resistance to these targeted therapies has limited their effectiveness. As a result, broader-spectrum inhibitors that act on multiple cancer-related kinases are now considered more promising therapeutic options.

Objective: We developed twenty-five new pyrrolopyrimidine derivatives featuring diverse substitution patterns to assess their potential as small-molecule inhibitors of the protein kinases CLK4 and HER2, both of which are significant therapeutic targets in metastatic breast cancer.

Method: Pyrrolopyrimidine derivatives were synthesized and purified by column chromatography. Their protein kinase inhibitory activity was evaluated through a radioactive ATPcompetition assay.

Results: The compounds were obtained through a multi-step synthetic procedure, concluding with substitution reactions. The effects of different substituents on the inhibitory properties of the observed protein kinases are analyzed and discussed.

Conclusion: Aniline-substituted derivatives exhibited the most potent activities, which were further modulated by N-substituted pyrroles. Consequently, we identified both selective and dual inhibitors of the target kinases, demonstrating activity in the nanomolar range.

背景:涉及蛋白激酶的细胞信号通路失调与癌症的发展有重要关系。因此,蛋白激酶已成为新型抗癌疗法的关键靶点。一系列激酶抑制剂,包括小分子和单克隆抗体,已经被开发出来。尽管早期的策略侧重于实现高特异性以尽量减少不良反应,但对这些靶向治疗的耐药性限制了它们的有效性。因此,作用于多种癌症相关激酶的广谱抑制剂现在被认为是更有希望的治疗选择。目的:我们开发了25种具有不同取代模式的新型吡咯嘧啶衍生物,以评估它们作为蛋白激酶CLK4和HER2小分子抑制剂的潜力,这两种蛋白激酶都是转移性乳腺癌的重要治疗靶点。方法:合成吡咯嘧啶衍生物,采用柱层析法纯化。通过放射性atp竞争试验评估其蛋白激酶抑制活性。结果:该化合物经过多步合成,以取代反应结束。分析和讨论了不同取代基对所观察到的蛋白激酶抑制性能的影响。结论:苯胺取代衍生物的活性最强,n取代吡咯进一步调节了苯胺取代衍生物的活性。因此,我们确定了选择性和双重抑制剂的目标激酶,显示在纳摩尔范围内的活性。
{"title":"Novel Pyrrolopyrimidines as Inhibitors of CLK4 and HER2: Targeting Promising Anticancer Pathways.","authors":"Jonathan Gries, Frank Totzke, Andreas Hilgeroth","doi":"10.2174/0115734064386606250410111952","DOIUrl":"https://doi.org/10.2174/0115734064386606250410111952","url":null,"abstract":"<p><strong>Background: </strong>Dysregulated cellular signaling pathways involving protein kinases are critically implicated in cancer development. Consequently, protein kinases have emerged as key targets for novel anticancer therapies. A range of kinase inhibitors, including small molecules and monoclonal antibodies, has been developed. Although early strategies focused on achieving high specificity to minimize adverse effects, resistance to these targeted therapies has limited their effectiveness. As a result, broader-spectrum inhibitors that act on multiple cancer-related kinases are now considered more promising therapeutic options.</p><p><strong>Objective: </strong>We developed twenty-five new pyrrolopyrimidine derivatives featuring diverse substitution patterns to assess their potential as small-molecule inhibitors of the protein kinases CLK4 and HER2, both of which are significant therapeutic targets in metastatic breast cancer.</p><p><strong>Method: </strong>Pyrrolopyrimidine derivatives were synthesized and purified by column chromatography. Their protein kinase inhibitory activity was evaluated through a radioactive ATPcompetition assay.</p><p><strong>Results: </strong>The compounds were obtained through a multi-step synthetic procedure, concluding with substitution reactions. The effects of different substituents on the inhibitory properties of the observed protein kinases are analyzed and discussed.</p><p><strong>Conclusion: </strong>Aniline-substituted derivatives exhibited the most potent activities, which were further modulated by N-substituted pyrroles. Consequently, we identified both selective and dual inhibitors of the target kinases, demonstrating activity in the nanomolar range.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicinal Chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1